Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

Reflecting on the robust synergies from the NuVasive merger, we anticipate that the latest news should positively impact the market sentiment toward GMED stock. Globus Medical has a market ...

Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

A Florida federal judge has issued a report and recommended that a sales representative pay more than $19 million to resolve ...

With the complementary strengths of Globus Medical engineering and NuVasive relations, education and training, GMED aims to outpace market growth, leading to accelerated EPS growth and an increase ...

The company currently has its sales operations distributed across 51 counties worldwide. With the complementary strengths of Globus Medical engineering and NuVasive relations, education and training, ...